ASAnastasia S. Sharlai

Anastasia S. Sharlai

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anastasia S. Sharlai has a total of 62 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Myoepithelial carcinoma of bones and soft tissues in children: a single-center experience

    by Valeriya O. Shestyuk, E. I. Konopleva, I. V. Sidorov, K. Yu. Sinichenkova, A. S. Sharlai, A. V. Panferova, N. V. Gegeliya, R. Kh. Abasov, M. M. Strozhenkov, A. Yu. Artemov, et al.

    Introduction. Myoepithelial сarcinoma (MC) is a rare and highly malignant neoplasm. Primary soft tissue involvement predominates in pediatrics (MCST), while MC of bones has been described in isolated cases. The rarity of MC combined with its polymorphic phenotype significantly challenge diagnosis and determine the absence of standardized treatment approaches. Aim: to analyze the specifics of diagnosis and treatment of children with MC at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Health of the Russian Federation. Material and methods. The study included 7 patients aged 1.3 to 14.2 years who were diagnosed with MC and registered between 2017 and 2024. Results and discussion. MC of soft tissue was diagnosed in 6/7 cases and MC of bones in 1/7. Five out of seven cases were localized, while 2/7 cases presented with distant metastases. In 3 cases a deletion of the SMARCB1 gene was identified, and in 1 case deletion of the EWSR1 gene was detected. Surgical resection proved to be the cornerstone of the treatment program for patients with MC (R0 – n = 3; R1 – n = 3; R2 – n = 1). 5 patients underwent external beam radiation therapy. In 4 cases of localized MC, courses of chemotherapy (ICpE) were administered as an adjuvant. In 1 case courses of ICpE and IVE were given perioperatively. In the first case of metastatic MCST courses of ICpE/IVE were also administered; and in the second case a combination of AP + vinorelbine was used. Follow-up outcomes: 4/7 patients are alive with 3/4 alive without events. Conclusion. The results of our study mostly align with international experience and emphasize the significance of local control, as well as the leading role of a multidisciplinary approach and multicenter data sharing in improving the diagnostic and therapeutic outcomes for patients with MC.

  • Rhabdomyosarcoma With Alveolar Morphology and a Novel NCOA1::ZNF143 Fusion in a 4‐Year‐Old Girl: A Case Report

    by Anastasia S. Sharlai, Tatyana S. Stradomskaya, Denis Y. Kachanov, Alexander E. Druy, Agnesa V. Panferova, Ruslan Abasov, Nikolai S. Grachev, Dmitry M. Konovalov

    Rhabdomyosarcoma with alveolar morphology is a diagnostically challenging tumor pattern, particularly in cases lacking canonical FOXO1 ‐associated fusions. In the current WHO framework, molecular fusion status plays a central role in classification and risk stratification. However, a subset of tumors lacks canonical rearrangements and harbors alternative genetic events. We report a case of a 4‐year‐old girl with a massive parameningeal rhabdomyosarcoma presenting with cranial nerve dysfunction and airway compromise. Histological examination confirmed rhabdomyosarcoma with alveolar morphology. Fluorescence in situ hybridization revealed no rearrangements of FOXO1 or PAX3 . Targeted RNA sequencing identified a novel NCOA1::ZNF143 fusion transcript. Despite intensive multimodal treatment including chemotherapy, radiotherapy, surgery, and metronomic therapy, the disease demonstrated multiple relapses with subsequent metastatic progression involving the spinal cord and central nervous system, ultimately leading to a fatal outcome.


  • Open Access

    Molecular features of mature B-cell non-Hodgkin lymphomas in children

    by L. S. Filatova, E. V. Volchkov, A. S. Sharlai, D. S. Abramov, Y. G. Abugova, N. V. Myakova

    This article is a review of the current literature on the molecular and genetic features of mature B-cell non-Hodgkin lymphomas (B-NHL) in children. This group of lymphoproliferative neoplasms is characterized by relative similarity in morphological and immunophenotypic features while exhibiting pronounced heterogeneity at the molecular and genetic level. Recent studies have enabled the identification of distinct biological subtypes of B-NHL, which has significantly changed approaches to their diagnosis and treatment. Our review examines the classification features of B-NHL in children, as well as key molecular genetic abnormalities and oncogenic signaling pathways responsible for the development of this group of diseases. This article also highlights the need for pediatric-specific studies of B-NHL and the development of specialized diagnostic and therapeutic approaches is emphasized.

  • An improved algorithm for genetic diagnostics of aggressive B-cell lymphomas in pediatric oncohematology: the experience of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology

    by A.S. Sharlai, E.V. Volchkov, D.S. Abramov, I.V. Sidorov, M.A. Baranova, N.V. Myakova, D.M. Konovalov

    Objective. To improve the stratification algorithm for aggressive B-cell lymphomas in children based on the analysis of genetic changes in the genes TP53, MYC, BCL2, BCL6 and the long arm of chromosome 11 (11q). Material and methods. A comprehensive cytogenetic and molecular genetic analysis of tumor samples was carried out using NGS and FISH methods. Rearrangements of the MYC locus and the presence of translocations with different chromosomal partners were investigated, as well as the analysis of mutations and deletions of the TP53 gene. The presence of MYC, BCL2, BCL6 rearrangements and 11q aberrations was investigated as part of the algorithm. Results. It has been shown that the classical translocation, t(8;14)(q24;q32) MYC::IGH, is detected in 77% of cases with typical Burkitt lymphoma histology. This translocation was not present in 23% of the samples. In a group of cases with classic histology of Burkitt lymphoma, where the t(8;14)(q24;q32) translocation was absent, rare genetic variations were identified — 11q gain/loss, and atypical FISH patterns indicative of complex genetic changes. TP53 mutations were detected in 26-30% of cases, localized mainly in the DNA-binding domain. A wide range of genetic changes has been identified, including monoallelic TP53 deletions and atypical FISH patterns that require attention and additional research. Conclusion. An improved diagnostic algorithm based on the combined use of FISH and NGS methods makes it possible to increase the accuracy of identification of genetic subtypes of aggressive B-cell lymphomas in children. This helps to categorize the diagnosis based on the molecular and genetic characteristics of the tumor, paving the way for improved prognosis and treatment effectiveness.


  • Open Access

    EWSR1::TFCP2-rearranged rhabdomyosarcoma of the skull bones: a clinical case and a literature review

    by Il'YA V. Sidorov, A. S. Sharlai, A. E. Druy, A. V. Panferova, R. Kh. Abasov, E. I. Chechev, D. V. Shevtsov, I. N. Vorozhtsov, N. S. Grachev, P. E. Trakhtman, et al.

    Introduction. Rhabdomyosarcoma with EWSR1::TFCP2 rearrangement is a rare type of tumor with myogenic differentiation, characterized by an aggressive clinical course and difficulties in diagnosis. Our literature review highlights its key features: a predominance of craniofacial localization, an extremely unfavorable prognosis, and frequent aberrant immunophenotypic patterns. Particular attention is paid to the heterogeneity of tumors with myogenic differentiation, which include a wide range of entities with various genetic abnormalities. This calls into question the traditional diagnostic criteria for rhabdomyosarcoma and require their revision, given the lack of standardized therapy and the complexity of differential diagnosis. Clinical case. Here, we present a clinical case of rhabdomyosarcoma with EWSR1::TFCP2 rearrangement in a 12-year-old girl with primary involvement of the skull base. The tumor showed aggressive growth with the involvement of sphenoid and latticed bones and intracranial spread. Histological examination revealed an epithelioid spindle cell tumor invading bone tissue and a myogenic immunophenotype with the expression of pan-cytokeratin. The diagnosis was confirmed by FISH and high-throughput RNA sequencing, which verified the presence of EWSR1::TFCP2 chimeric transcript. Conclusion. The lack of standardized therapy and the difficulty of differential diagnosis underscore the need for further research to improve understanding, classification, and treatment of this type of rhabdomyosarcoma.

  • Open Access

    Aspects of molecular diagnostics and clinical characteristics of children and adolescents with CIC-rearranged sarcoma

    by Ksenia Yu. Sinichenkova, A. V. Panferova, R. Kh. Abasov, N. V. Gegeliya, I. V. Sidorov, A. S. Sharlay, D. M. Konovalov, D. V. Litvinov, G. A. Novichkova, A. E. Druy

    Introduction. CIC-rearranged sarcoma is the most aggressive tumor of all undifferentiated small round cell sarcomas (USRCSs) of bone and soft tissue, characterized by a high incidence of distant metastases and disease progression during first-line treatment. In this article, we describe clinical, biological and molecular characteristics and tools for quick and precise molecular diagnosis. Aim – to evaluate the molecular features of sarcoma with CIC gene rearrangement and to investigate the clinical and prognostic characteristics in children with CIC-rearranged sarcoma. Materials and methods. We analyzed the clinical and molecular characteristics of 20 patients with the following initial morphological diagnoses: USRCS, undifferentiated spindle cell sarcoma, CIC-rearranged sarcoma. The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation. Results. Fourteen out of 20 patients were diagnosed with CIC-rearranged sarcoma using molecular diagnostic assays. In 12 out of these 14 patients direct molecular markers were identified using RNA sequencing, in 2 patients the diagnosis was confirmed using NanoString’s molecular barcoding technology. Survival analysis was performed for 12 out of 14 patients; the 3-year overall and disease-free survival rates were 34.4 ± 16.0% and 23.8 ± 14.6%, respectively. Conclusion. Patients suspected of CIC-rearranged sarcoma always require comprehensive molecular diagnostic testing to avoid misdiagnosis. CIC-rearranged sarcoma has the most aggressive clinical course of all USRCSs, is characterized by early disease progression and requires a more intensive treatment approach.

  • Neuroblastoma: prevalence of genetic alterations in different histological groups

    by M.A. Baranova, A.S. Sharlai, D.M. Konovalov

    Neuroblastoma is a disease characterized by clinical, histological and genetic heterogeneity. The morphological type, immunohistochemical expression of proteins (MYCN, MYC) and molecular genetic characteristics of the tumor (the status of the MYCN gene and chromosomal regions 1p and 11q) are key to predicting the course of the disease and choosing therapy. Objective. Estimate the prevalence of the most clinically significant genetic events in different histological groups and among neuroblastomas in general and to demonstrate rarer genetic findings. Material and methods. A total of 233 cases of patients with neuroblastoma, for whom the histological conclusion and the results of cytogenetic examination by FISH (the status of the MYCN gene and chromosomal regions 1p and 11q) were known, were analyzed. Based on these data, the cases were divided into favorable and unfavorable histological groups, in each of which the presence of genetic abnormalities was analyzed. Also, 28 cases of patients with large cell neuroblastoma were analyzed, for whom the histological conclusion, MYCN gene status, immunohistochemical expression of MYC protein and the results of cytogenetic study of MYC gene status by FISH were known. Results. MYCN gene amplification, 1p deletion/imbalance and 11q deletion/imbalance are more common in tumors from the unfavorable morphological group. Aberrations of the chromosomal region 1p and MYCN amplification are events that often occur together, while 11q aberrations, on the contrary, have an inverse correlation with MYCN amplification. 11q deletion/imbalance is more often detected in tumors with MYCN gain. In 4 cases, 1p and 11q chromosomal aberrations were detected in the same tumor, all in the unfavorable histological group. Two cases with chromosomal aberrations in stromal cells were also identified. Expression of MYC protein was detected in 5 cases, of which 2 showed amplification of the MYC gene.

  • Open Access

    Sympathoblasts and their malignant progeny: the cellular mosaic of neuroblastoma

    by Dmitry M. Konovalov, Anastasia S. Sharlai, Pavel E. Trakhtman

    This review provides a comprehensive analysis of current knowledge on neuroblastoma in the context of embryonic development of the sympathoadrenal system. The evolution of scientific concepts regarding this tumor is traced from its first descriptions in the second half of the 19th century to the present day. The review outlines the conceptual framework of the modern understanding of neuroblastoma as a consequence of disrupted differentiation of neural crest cells. Particular attention is given to embryological aspects of sympathoadrenal system development, including neural crest cell migration, differentiation under the influence of external signals, and the formation of bipotential sympathoblasts capable of generating both neuronal and mesenchymal lineages. A substantial portion of the review focuses on the cellular heterogeneity of neuroblastoma, manifested by the coexistence of H-type (adrenergic) neuronal cells and C-type (mesenchymal) adhesive cells. The authors analyze findings from recent studies and highlight challenges in identifying tumor cell populations, emphasizing the need for validated species-specific markers. The review underscores the importance of integrating knowledge of key embryogenic stages with modern genomic technologies to develop more effective therapeutic strategies for this aggressive pediatric tumor.

  • Open Access

    RET-rearranged spindle cell soft tissue sarcoma in children: description of a clinical case and literature review

    by O. S. Zatsarinnaya, A. E. Druy, D. M. Konovalov, N. A. Andreeva, A. V. Panferova, A. S. Sharlai, K. Yu. Sinichenkova, T. V. Shamanskaya, V. Yu. Roshchin, A. P. Shcherbakov, et al.

    Soft tissue sarcomas (SMTs) represent a heterogeneous group of malignant tumors of mesenchymal origin. The widespread introduction of next-generation sequencing techniques, including RNA sequencing, into clinical practice has led to the description of a variety of SMTs with rearrangements of genes encoding various kinases. The present article describes the clinical case of a 3-year-old patient with a low-grade spindle cell sarcoma with a detectable MYH10::RET RNA transcript. The literature review describes the role of the RET gene in the pathogenesis of malignant neoplasms, with emphasis on soft tissue tumors, and presents the clinical, molecular and genetic characteristics of pediatric cases of SMT with RET gene rearrangements and the results of their therapy. The role of various molecular oncology techniques in the identification of kinase gene rearrangements, including RET, is discussed.

  • Gastric tumors with GLI1 gene alterations (plexiform fibromyxoma and gastroblastoma). Case report and literature review

    by I.V. Sidorov, A.S. Sharlai, D.M. Konovalov

    Plexiform fibromyxoma (PFM) and gastroblastoma (GB) are rare gastric tumors with a specific MALAT1::GLI1 rearrangement, included in the conditional spectrum of neoplasms with alterations of the GLI1 gene. The article presents a clinical case of PFM in a 6-year-old girl and a literature review highlighting current data on the morphology, immunophenotype and molecular genetic characteristics of PFM and GB. Despite the common genetic anomaly, differences in the morphology and clinical course of these tumors indicate the need for further research to clarify their relationship and potential reclassification in the light of new data on tumors with GLI1 gene abnormalities. Integrating the accumulated knowledge about tumors with GLI1 gene alterations into diagnostic algorithms and therapeutic approaches will help improve the treatment outcomes of patients with these rare neoplasms.